Prophylactic strategies for hepatitis B patients undergoing liver transplant: A cost-effectiveness analysis
Open Access
- 20 April 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 12 (5) , 736-746
Abstract
Hepatitis B immunoglobulin with lamivudine prophylaxis (LAM/HBIG) is effective in preventing Hepatitis B (HBV) recurrence posttransplant but is expensive and inconvenient. Lamivudine-resistant HBV, which has limited the usefulness of lamivudine monoprophylaxis in transplant, can now be effectively controlled with adefovir dipivoxil. We performed a cost-effectiveness analysis on the strategies of lamivudine prophylaxis with adefovir rescue(LAM/ADV) compared to combination LAM/intravenous fixed high-dose HBIG prophylaxis(LAM/ivHBIG) or LAM/intramuscular HBIG prophylaxis(LAM/imHBIG). Markov modeling was performed with analysis from societal perspective. Probability rates were derived from systematic review of the literature and cost taken from MEDICARE database. Outcome measures were incremental cost-effectiveness ratio(ICER) and cost to prevent each HBV recurrence and death. Analysis was performed at 5 years posttransplant as well as at end of life expectancy (15 years). Combination LAM/ivHBIG cost an additional USD562,000 at 15 years, while LAM/imHBIG cost an additional USD139,000 per patient compared to LAM/ADV. Although there is an estimated increase in recurrence of 53% with LAM/ADV and 7.6% increased mortality at the end of life expectancy (15 years), the ICER of LAM/ivHBIG over LAM/ADV treatment is USD760,000 per quality-adjusted life-years and for LAM/imHBIG, USD188,000. Cost-effectiveness is most sensitive to cost of HBIG. Lamivudine prophylaxis with adefovir dipivoxil salvage offers the more cost-effective option for HBV patients undergoing liver transplant but with higher recurrence and death rate using a model that favors LAM/HBIG. Lowering the cost of HBIG maintenance will improve cost-effectiveness of LAM/HBIG strategy. In conclusion, a tailored approach based on individual risks will optimize the cost-benefit of HBV transplant prophylaxis. Liver Transpl 12:736–746, 2006. © 2006 AASLD.Keywords
This publication has 24 references indexed in Scilit:
- 57 Long-term incidence of adefovir dipivoxil (ADV) resistance in chronic hepatitis B (CHB) patients after 144 weeks of therapyJournal of Hepatology, 2004
- A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantationLiver Transplantation, 2001
- An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapyLiver Transplantation, 2000
- Outcome of lamivudine resistant hepatitis B virus infection in liver transplant recipients in SingaporeGut, 2000
- Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipientGut, 2000
- Interpretation of cost-effectiveness analysesJournal of General Internal Medicine, 1998
- Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis†Hepatology, 1998
- Liver transplantationAlimentary Pharmacology & Therapeutics, 1997
- Markov Models in Medical Decision MakingMedical Decision Making, 1993
- Hepatitis B virus reinfection after orthotopic liver transplantationJournal of Hepatology, 1992